| PAKs | P21-activated kinases |
| PDA | Pancreatic ductal adenocarcinoma |
| TME | Tumour microenvironment |
| CSCs | Cancer stem cells |
| 5-FU | 5-fluorouracil |
| TKIs | Tyrosine kinase inhibitors |
| PFS | Progression-free survival |
| OS | Overall survival |
| MVD | Microvessel density |
| GTP | Guanosine triphosphate |
| MVI | Microvessel integrity |
| SEMA3A | Semaphorin 3A |
| SalB | Salvianolic acid B |
| HRG | Histidine-rich glycoprotein |
| RGS5 | G-Protein Signalling 5 |
| Cda | Cytidine deaminase |
| EMT | Epithelial–mesenchymal transition |
| VSMCs | Vascular smooth muscle cells |
| CSF2 | Colony stimulating factor 2 |
| HRG | Heregulin β1 |
| HIF-1α | Hypoxia-inducible factor 1 alpha |
| JMJD6 | Jumonji domain-containing protein 6 |
| MMP9 | Matrix metalloproteinases 9 |
| CAFs | Cancer-associated fibroblasts |
| PSCs | Pancreatic stellate cells |
| KO | Knockout |
| KD | Knockdown |
| GBM ECs | Glioblastoma multiforme endothelial cells |
| IHC | Immunohistochemical |